Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Discontinuing Oral Mesalazine in Ulcerative Colitis Patients on Vedolizumab Maintenance
ChiCTR2500111500Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vedolizumab and Salcrozine in autoimmune colitis (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Clinical remission response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
vedolizumabSalcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2500111500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111500.